Published in Antimicrob Agents Chemother on August 01, 2001
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun (2002) 1.85
Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol (2001) 1.67
The MAPK Hog1p modulates Fps1p-dependent arsenite uptake and tolerance in yeast. Mol Biol Cell (2006) 1.57
Vaccines to combat the neglected tropical diseases. Immunol Rev (2011) 1.55
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother (2003) 1.29
Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun (2005) 1.09
Transcriptional activation of metalloid tolerance genes in Saccharomyces cerevisiae requires the AP-1-like proteins Yap1p and Yap8p. Mol Biol Cell (2004) 1.06
Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun (2003) 1.02
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother (2009) 1.01
Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother (2003) 0.99
Activity of Cuban Plants Extracts against Leishmania amazonensis. ISRN Pharmacol (2012) 0.93
Identification and characterization of a novel deoxyhypusine synthase in Leishmania donovani. J Biol Chem (2009) 0.91
The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania. Cell Stress Chaperones (2004) 0.91
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis (2013) 0.89
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother (2002) 0.89
Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect Immun (2006) 0.87
TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog (2012) 0.87
Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun (2007) 0.86
Optimizing efficacy of Amphotericin B through nanomodification. Int J Nanomedicine (2007) 0.83
First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. Parasitol Res (2013) 0.83
Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis. PLoS Negl Trop Dis (2012) 0.81
Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. Korean J Parasitol (2006) 0.80
Antileishmanial activity of some plants growing in Algeria: Juglans regia, Lawsonia inermis and Salvia officinalis. Afr J Tradit Complement Altern Med (2013) 0.80
A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag (2009) 0.78
In vitro and in vivo activity of an organic tellurium compound on Leishmania (Leishmania) chagasi. PLoS One (2012) 0.78
In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res (2010) 0.77
Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Vaccine (2016) 0.76
Host response of platelet-activating factor receptor-deficient mice during pulmonary tuberculosis. Immunology (2003) 0.76
UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj J (2008) 0.76
To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). PLoS One (2017) 0.75
Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80
The regulation of immunity to Leishmania major. Annu Rev Immunol (1995) 8.05
Leishmaniasis. Lancet (1999) 7.20
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med (1999) 5.02
Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis (1997) 4.23
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest (1993) 3.15
Clinical spectrum of Leishmaniasis. Clin Infect Dis (1996) 2.94
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis (1999) 2.92
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med (1990) 2.67
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med (1999) 2.51
Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med (1996) 2.36
CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 2.31
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 2.15
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 2.11
Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol (1991) 2.00
Visceral leishmaniasis in immunocompromised hosts. Am J Med (1987) 1.99
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol (1988) 1.87
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother (1981) 1.82
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A (1978) 1.82
Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med (1997) 1.80
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother (1999) 1.77
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis (1996) 1.75
Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med (1995) 1.74
B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J Immunol (2000) 1.73
Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol (1990) 1.71
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Tropical medicine. BMJ (2000) 1.67
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol (1998) 1.65
Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today (1993) 1.64
Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun (1994) 1.62
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 1.60
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med (1997) 1.59
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A (1999) 1.59
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun (1998) 1.57
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem (1998) 1.55
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
An axenic amastigote system for drug screening. Antimicrob Agents Chemother (1997) 1.50
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother (1995) 1.49
Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother (1996) 1.49
IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine (2000) 1.47
A tissue culture system for the growth of several species of Leishmania: growth kinetics and drug sensitivities. Am J Trop Med Hyg (1988) 1.47
The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur J Immunol (1998) 1.46
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun (2000) 1.44
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother (1998) 1.44
Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology (1996) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol (1998) 1.40
Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol (1996) 1.39
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun (2000) 1.39
Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol (1998) 1.38
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother (1996) 1.37
The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother (1995) 1.37
Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis (1990) 1.37
Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis (1988) 1.35
Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun (1995) 1.35
The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol (1988) 1.33
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis (2000) 1.32
Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun (1998) 1.32
Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol (2000) 1.32
Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis (1987) 1.32
Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol Med (2000) 1.31
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg (2002) 1.31
Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol (1992) 1.31
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis (2000) 1.31
Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol (1993) 1.29
Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis (2000) 1.29
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis (1993) 1.29
Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani. Infect Immun (1999) 1.27
Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg (1999) 1.26
Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother (1999) 1.25
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2000) 1.24
The importance of TGF-beta in murine visceral leishmaniasis. J Immunol (1998) 1.24
Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother (1991) 1.24
TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J Immunol (2000) 1.24
Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol (1999) 1.23
Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis (1993) 1.23
Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc Natl Acad Sci U S A (1999) 1.23
Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol (1999) 1.22
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice. J Immunol (1987) 1.21
Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis (1995) 1.20
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis (1997) 1.20
Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother (1997) 1.18
IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol (2000) 1.17
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 1.15
The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol (1987) 1.15
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother (1992) 1.15
The current status of antiparasite chemotherapy. Parasitology (1997) 1.15